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Abstract
Background and Objectives Knowledge obtained via
high-throughput technologies, used for tumor genome
sequencing or identifying gene expression and methylation
signatures, is clinically applicable thanks to molecular
characterization in the context of tumor development and
progression. This study was conducted to assess the impact
of specific KRAS mutation in codons 12 and 13 on clinical
outcome of chemotherapy and radiotherapy in colorectal
cancer patients.
Methods A total of 239 samples of colorectal adenocar-
cinoma underwent histological evaluation and DNA
isolation.
Results and Conclusions Patients with a mutation in
KRAS codon 13 experienced worse outcome than those
with a mutation in KRAS codon 12. Moreover, the cases
of mutations in KRAS codons 12 or 13 were associated
with a significantly higher mortality than the cases of
wild-type KRAS, and some patients with KRAS mutated
in codon 12 had an exceptionally long overall survival.
Finally, primary preoperative radiation therapy followed
by surgery significantly increased overall survival more
efficiently than surgery followed by chemotherapy. This
should be investigated in further studies. The fact that all
patients treated with radiotherapy ? surgery were alive,
again focused our attention on the effect of preoperative
radiation therapy on the prognosis for colorectal cancer
patients. However, the number of patients in this sub-
group is too small to allow any specific explanation for
this observation. We should, rather, point out a problem
for further investigation.
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Key Points
We determined the differences in treatment outcome
in 100 colorectal cancer patients with wild-type
(WT) KRAS and 139 patients with mutations in exon
2. The median overall survival of the patients with
KRAS mutations in codons 12 or 13 was shorter
versus patients with WT KRAS (19 vs. 29 months)
We assessed whether tumors with mutations in
KRAS codon 12 represent a less aggressive subtype
compared with those with mutations in KRAS codon
13. In fact, patients with KRAS mutations in
codon 12 had longer median overall survival
compared with the KRAS mutated in codon 13
(25 vs. 18 months, respectively)
Patients with KRAS mutation have better median
overall survival when treated with
radiotherapy ? surgery than
surgery ? chemotherapy (32 vs. 19 months,
respectively)
1 Introduction
High-throughput technologies such as microarrays or new-
generation sequencing techniques enable the determination
of the genomic sequences of tumors or the identification of
gene expression and methylation signatures. However, the
unprecedented use of such knowledge in clinical practice is
not enabled by the sole detection of new mutations, but
rather by their profound molecular characterization in the
context of tumor development and progression. The char-
acterization of mutations in the APC gene that cause
familial adenomatous polyposis of the large intestine has
led the way for routine oncological prophylaxis. Prophy-
lactic tests have been expanded with mutation analysis in
DNA mismatch repair genes, such as MLH1, MSH2, MSH6
or PMS2. In the last decade, gene expression analyses were
conducted in order to predict the likelihood of disease
recurrence, especially in stage II colon cancer patients
treated with surgery and fluorouracil/leucovorin [1].
Finally, for 15 years, attempts have been made to create the
CpG island methylator phenotype for colorectal cancer [2].
However, it was the discovered correlation between
mutations in the KRAS gene and the efficacy of treatment
using a monoclonal antibody targeting epidermal growth
factor receptor (EGFR), such as panitumumab and cetux-
imab, that became a milestone in personalized oncology.
Colorectal cancer cells carrying somatic KRAS mutations
[3] are less likely to respond to EGFR inhibition. On the
other hand, recent studies show that wild-type (WT) KRAS
status is not the only factor crucial for patient qualification
for targeted therapy with an anti-EGFR monoclonal anti-
body. Patients bearing BRAF or KRAS mutations (in exon 3
and 4, respectively) had poorer response rate to cetuximab
and irinotecan compared with the WT KRAS and BRAF
patients [3]. Also, high-throughput technologies (such as
massively parallel tumor multigene sequencing) were used
to evaluate the response to anti-EGFR monoclonal anti-
bodies. In this study, treatment with panitumumab was
associated with longer progression-free survival (PFS)
among the WT KRAS (codons 12/13/61), WT NRAS and
WT BRAF patients [4].
In this study, we wanted to evaluate whether tumors
with mutations in KRAS codon 12 represent a less
aggressive subtype compared with those with mutations in
KRAS codon 13, and correlate patients with KRAS muta-
tions in codon 12 or 13 versus WT KRAS. Finally, we
wanted to access the differences in the treatment outcome
in KRAS WT and mutated metastatic colorectal cancer
(mCRC) patients.
2 Methodology
2.1 Patient Selection
Overall, 239 patients with an histologically established
diagnosis of colorectal adenocarcinoma (after surgery), for
whom the collection of tissue samples was part of their
routine care and treatment, were included in the study.
The reviewed cohort of WT KRAS (n = 100) and
mutant KRAS (n = 139) specimens of colorectal carci-
noma was obtained from the Molecular Oncology and
Genetics Unit, Department of Tumor Pathology and
Pathomorphology, The F. Lukaszczyk Oncology Center,
Bydgoszcz, Poland. Informed consent for mutation testing
was obtained from all patients.
All patients were treated using surgery (between July
2006 and December 2012) and adjuvant therapy (chemo-
therapy standard or radiation therapy). Progression of
metastatic disease occurred in all patients, at different
times after the first surgery. Treatment with cetuximab or
panitumumab was carried out between July 2008 and
February 2013 (anti-EGFR agent in third-line of chemo-
therapy was used). Table 1 presents the clinical charac-
teristics of all 239 patients.
In each case, a representative sample of the adenocar-
cinoma tissue area, a formalin-fixed, paraffin-embedded
(FFPE) block or a cytology specimen was identified by a
pathomorphologist and scraped for DNA isolation. Histo-
logical evaluation and DNA isolation were performed as
previously described [5].
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2.2 Mutation Analysis
Each individual case was evaluated for KRAS mutations in
exon 2 (codons 12 and 13) using one of the following
methods of mutation analysis: single-strand conformation
polymorphism (SSCP), Sanger sequencing, or CE-IVD
polymerase chain reaction (PCR)-related methods: strip test
containing allele-specific probes (ViennLab) and real-time
PCR methods using Taqman probes (EntroGen, Inc.), high
resolution melting-curve analysis (TibMolBiol) and allele-
specific amplification ARMS and detection by Scorpions
technology (Therascreen). Additional analysis of mutations
in KRAS exon 3 or BRAF exon 15 was performed for a
number of selected patients diagnosed with mCRC between
September 2012 and February 2013, previously evaluated
using the real-time PCR methodology (Entrogen, Inc.) or
PCR with reverse-hybridization (ViennaLab). Uncertain
results were double-checked in a second analysis performed
using another molecular method from the list above.
2.3 Statistical Analysis
For statistical analysis, the STATISTICA (version 10.0)
computer software (StatSoft, Inc.) was used. Differences
between the categorized groups were assessed using the
log-rank test. Correlations between overall survival and
the results of KRAS mutation analysis in codons 12 and
13 were estimated using the Kaplan–Meier estimator. The
results were considered statistically significant at
p \ 0.05.
3 Results
3.1 Characteristics of the Patients
Clinical characteristics for 239 patients, such as mean age,
sex, tumor site, and treatment, are provided in Table 1. The
way in which colorectal cancer affects the daily living
abilities of the patients was assessed using the Eastern
Cooperative Oncology Group (ECOG) performance status
(Table 1) [http://ecog.dfci.harvard.edu/general/perf_stat.
html]. The majority of mCRC patients (83 %) were out-
patients and were able to carry out work of a light or
sedentary nature, while the second group (14 %) repre-
sented ECOG grade 2, in which patients are capable of all
self-care but unable to carry out any work activities. The
smallest group (3 %) belonged to patients capable of only
limited self-care (ECOG grade 3). No completely disabled
patients were included in this study.
Table 1 Clinical patients
characteristics
SD standard deviation, ECOG
Eastern Cooperative Oncology
Group, EGFR epidermal growth
factor receptor
Patients characteristics Study population (n = 239)
Age (year), mean ± SD 59.5 (24–77)
Sex (male/female) 142/97
KRAS wild-type (male/female) 63/37
KRAS mutated (male/female) 78/61
No. of patients
Mutation
Codon 12 109
Codon 13 30
Primary tumor site
Colon 129
Rectum 110
Primary tumor resected
Colon 115 (87 %)
Rectum 101 (92 %)
ECOG performance status
1 198 (83 %)
2 34 (14 %)
3 7 (3 %)
4 0
Adjuvant treatment anti-EGFR
Radiotherapy 52
Chemotherapy 197
Panitumumab 25
Cetuximab 75
Impact of Specific KRAS Mutation in Exon 2 on Clinical Outcome 561
3.2 Specimen Evaluation and Molecular Analysis
of KRAS Exon 2
A total of 239 FFPE and cytology samples were qualified for
molecular analysis using quantitative scale (QS), and the
percentage of tumor cells (PTC) by pathomorphologists at the
F. Lukaszczyk Oncology Center, as previously described [5,
6]. Among the 239 samples qualified for the determination of
the presence of KRAS mutations, 139 (57.4 %) had a somatic
mutation in codon 12 or 13. The majority of KRAS mutations
were diagnosed in codon 12 (n = 109), compared with
30 specimens with mutations in codon 13. Most of the
mutations (95.8 %) were detected with the PTC at 10 % or
above. Furthermore, real-time PCR allowed the detection of
KRAS p.G12D, p.G12V, p.G12A, or p.G12D in six samples
with a low PTC (below 10 %).
3.3 Impact of Specific KRAS Mutation in Exon 2
on Clinical Outcome
This study was conducted to assess whether tumors with
mutations in KRAS codon 12 represent a less aggressive
Fig. 1 Kaplan–Meier curves of
KRAS status. a In the subset of
patients with mutant KRAS
tumors, mutation in codon 12 is
not correlated with survival.
b Comparing overall survival in
patients with mutant KRAS
tumors versus wild-type KRAS
tumors, mutations in codons 12
or 13 are significantly
correlated with better survival.
OS overall survival
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subtype compared with those with mutations in KRAS
codon 13. A comparative analysis of overall survival in
correlation with potential differences was conducted
between the patient groups with mutant and WT KRAS.
The median overall survival in patients with KRAS
mutations in codon 12 was better compared with patients
with KRAS mutations in codon 13 (25 vs. 18 months,
respectively) [Fig. 1a]; the results were at the borderline of
statistical significance. Unusually long overall survival
(above 80 months, up to 160 months) was observed in
11 patients of the group with codon 12 mutations.
Various types of KRAS mutations were tested for their
potentially different effect on the patients’ overall survival.
Median overall survival of patients with KRAS mutations in
codons 12 or 13 was 19 months, while that of patients with
WT KRAS was 29 months (p = 0.03, log-rank test)
[Fig. 1b].
3.4 Long-Term Results Depending on the Method
of Treatment
We assessed whether Polish patients with a new diagnosis
of colorectal cancer, after surgical removal of the primary
tumor with KRAS mutations in codon 12 or 13, might have
a better prognosis regarding overall survival than patients
with WT KRAS. To learn the effect of the treatment regi-
men on the remote results, we performed a comparative
analysis in the group of patients with KRAS mutated in
codon 12 according to the administered therapy (Fig. 2,
blue and green lines). As it occurred, the median overall
survival of patients carrying the somatic KRAS mutation
and treated with radiotherapy ? surgery (RT ? SUR) was
considerably better than that of patients treated with sur-
gery ? chemotherapy (SUR ? CT) [32 vs. 19 months,
respectively].
Finally, we sought to determine the differences in the
treatment outcome in 100 colorectal cancer patients with
WT KRAS and 139 patients with mutations in codon 12
or 13. It was also revealed that in the subgroup of patients
carrying a KRAS mutation in codon 13 and treated with
RT ? SUR (a small group of seven patients), all patients
remained alive (Fig. 2, the dotted purple line). Among
patients with KRAS mutated in codon 13 treated with
SUR ? CT, 70 % remained alive (Fig. 2, red line). How-
ever, median overall survival in both subgroups did not
differ significantly.
4 Discussion
In the recent years, the recommendations for somatic
mutation analysis, conducted as part of the qualification of
patients for immunotherapy using monoclonal antibodies,
were limited only to the second exon of the KRAS gene.
Advances in targeted therapies in oncology, as well as
constantly increasing knowledge in the field of colorectal
cancer biology, have participated in the expansion of the
range of analyses in molecular diagnostics with KRAS
exons 3 and 4 and new genes, such as NRAS or BRAF
(Fig. 3). On the other hand, before this expansion of the
panel of analyzed somatic mutations, some patients car-
rying mutations in KRAS, BRAF, or NRAS had initiated
Fig. 2 Kaplan–Meier curves of
KRAS status: mutated in
codons 12 or 13, according to
the method of treatment. SUR
surgery, CT chemotherapy, RT
radiation therapy, OS overall
survival
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treatment with cetuximab or panitumumab [3, 5], which
resulted in the development of primary resistance. How-
ever, patients with WT BRAF/NRAS/PI3KCA and KRAS
tumors have the highest chance of response to the epider-
mal growth factor receptor-targeted therapy [7–9]. It is
known that KRAS mutations in codon 12 are associated
with a mucinous phenotype of colorectal cancer. A sig-
nificant characteristic of the colorectal cancers associated
with KRAS codon 13 mutations is that they are rather non-
mucinous, but characterized as more aggressive tumors
with a greater metastatic potential [9, 10]. In fact, we
observed a 7-month difference in overall survival in favor
of patients with a KRAS mutation in codon 12. A more
precise analysis of this group might determine a subtype of
mutation with a particularly good prognosis. The results of
De Roock et al. from pooled analysis from seven clinical
trials [11], and detailed retrospective analysis of colorectal
patients with KRAS codon p.G13D mutation who received
cetuximab [12], indicate that there is no black and white
dogma that only mCRC patients with WT KRAS benefit
from cetuximab [13]. Interestingly, similar results to ours,
in which patients with a mutation in KRAS codon 13
experienced worse outcome compared with the KRAS
codon 12 mutants, were observed in lung cancer [14].
Second, we demonstrated that the cases of mutations in
KRAS codons 12 or 13 were associated with a significantly
Fig. 3 Molecular diagnostics in colorectal cancer: examples of
mutation analysis in the KRAS, BRAF, and NRAS genes. a Analysis
of KRAS mutations in codons 12 and 13 using the real-time PCR
methodology with melting curve analysis. No KRAS mutations
detected in any of the two codons (the presence of the following
mutations was tested: 12D, 12C, 12V, 12A, 12R, 12S, 12T, 13D, 12D/
13D and 13C). Each curve represents the time course of the real-time
PCR assay. Line 1 represents the detection of a control WT amplicon,
line 2 represents control 13C, line 3 represents control 12C, and
line 4 represents sample of interest with WT KRAS status. b Analysis
of the BRAF V600E and KRAS codons 12 and 13 mutations using
PCR with reverse hybridization. Blue line positive signal detected
with a control PCR reaction, no mutation detected in KRAS
codons 12 or 13 or BRAF V600E. The tested mutations are listed
on the right. c, d Analysis of NRAS mutations in exons 2, 3, and 4
using allele-specific primers. c Filter: FAM 465-510; amplification
curves represent the following PCs in exon 2: G12C, G12D, G12S,
G13V, G13R; in exon 3: Q61K, Q61R, Q61L, Q61H; and in exon 4:
A146T (Cp in the range 27.03–29.03). Baselines represents no
amplification with primers complementary to mutant NRAS variants
in exons 2, 3, and 4, and NTC. d IC for VIC/yellow reporter
measuring DNA load of the tested sample. Amplification curves
represent internal controls for each of the 10 reactions (Cp in the
range 29.23–29.54), flat lines represent NTC. PCR polymerase chain
reaction, WT wild-type, PCs positive controls, IC internal controls
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higher mortality compared with the cases of WT KRAS
(median overall survival: 19 vs. 29 months, respectively;
Fig. 1b). In the group of patients with mutations in KRAS
codon 12 participating in our study, exceptionally long
overall survival (up to 160 months) was observed in
11 patients. This suggests that in the group with KRAS
mutated in codon 12 there is a subgroup of several patients
with a particularly good prognosis. The most comprehen-
sive explanation for this observation would be provided by
thorough genotyping of KRAS codon 12 and BRAF/NRAS/
PI3KCA somatic mutation screening to determinate muta-
tion status that correlates with the good prognosis. For
example, mutations c.35G[A (p.G12D) and c.35G[C
(p.G12A) [Fig. 1a] confer less potent transforming ability
than c.34G[C (p.G12R) and c.35G[T (p.G12V) [15]. Our
observations emphasize the importance of the fact that
various mutations (even in a single exon) may contribute to
different characteristics of the tumor, supporting its unique
morphology [12, 16]. A growing number of reports
underline the prognostic and predictive value of the
information derived not only from the analysis of somatic
mutations, but also from the analysis of miRNA expression
[17].
Surprising results from this study were obtained by
comparing overall survival of patients divided into sub-
groups according to the KRAS mutations in codons 12
or 13 and the administered therapy. All patients were
subjected to surgical resection (SUR) of colorectal cancer
combined with adjuvant therapy in the form of standard
chemotherapy (oxaliplatin) [CHT] or primary preoperative
radiation therapy (RH) followed by surgery (SUR). It
seems that tumor responsiveness to therapy (radiation
versus chemotherapy) may be predicted by DNA content
(mutation in KRAS codon 13). On the other hand, it has
been recently showed on a similar number of CRC patients
that tumor ploidy is not associated with tumor response to
radiation [18]. Therefore, more detailed molecular analysis
(somatic mutations, microsatellite instability, chromosomal
instability and genome-wide association studies) on a
bigger cohort of CRC patients should be performed to
evaluate and better understand the response to
radiotherapy.
5 Conclusions
We showed worse median overall survival of patients with
KRAS mutations in exon 2 than KRAS WT. In particular,
patients with mutation in codon 13 and treated without
radiotherapy had the lowest overall survival from all
studied groups. Also, the fact that all patients treated with
radiotherapy and surgery were alive, again focused our
attention on the effect of preoperative radiation therapy on
the prognosis for colorectal cancer patients. However, the
number of patients in this subgroup was too small to allow
any specific explanation of this observation. We should,
rather, point out a problem for further investigation.
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